Evaluation of core and surface body temperatures, prevalence, onset, duration and severity of hot flashes in men after bilateral orchidectomy for prostate cancer

International Braz J Urol

Volumn 34, Issue 1, 2008, Pages 15-22

  Aziz, Naseem A ^a   Heyns, Chris F ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Androgen; Hot flashes; Orchidectomy; Prostate cancer

Indexed keywords

EID: 41549121471     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382008000100004     Document Type: Article

References (26)

1. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JW: Hormonal profiles after the menopause. Br Med J. 1976; 2: 784-7.
2. Casper RF, Yen SS, Wilkes MM: Menopausal flushes: a neuroendocrine link with pulsatile luteinizing hormone secreation. Science. 1979; 205: 823-5.
3. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990; 592:52-86.
4. Abdalla HI: Pathophysiology of hot flushes. Obstet Gynecol Surv. 1985; 40: 338-43.
5. Kouriefs C, Georgiou M, Ravi R: Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int. 2002; 89: 379-83.
6. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D: Hot flushes. Lancet. 2002; 360: 1851-61.
7. Molnar GW: Body temperatures during menopausal hot flashes. J Appl Physiol. 1975; 38:499-503.
8. Frodin T, Alund G, Varenhorst E: Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer. Prostate. 1985; 7: 203-8.
9. Karling P, Hammar M, Varenhorst E: Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol. 1994; 152: 1170-3.
10. Schow DA, Renfer LG, Rozanski TA, Thompson IM: Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J. 1998; 91: 855-7.
11. Spetz AC, Hammar M, Lindberg B, Spangberg A, Varenhorst E; Scandinavian Prostatic Cancer Group-5 Trial Study: Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol. 2001; 166: 517-20.
12. Spetz AC, Pettersson B, Varenhorst E, Theodorsson E, Thorell LH, Hammar M: Momentary increase in plasma calcitonin gene-related peptide is involved in hot flashes in men treated with castration for carcinoma of the prostate. J Urol. 2001; 166: 1720-3.
13. Suzuki K, Kobayashi M, Tokue A: Clinical evaluation of hot flushes developing during endocrine therapy for prostate carcinoma. Nippon Hinyokika Gakkai Zasshi. 2003; 94: 614-20.
14. Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K: Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol. 2004; 11: 735-41.
15. McCullagh EP, Renshaw JF: The effects of castration on the adult male. JAMA. 1934; 103: 1140-3.
16. Huggins C, Hodges C. Studies on prostatic cancer 1: the effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-7.
17. Charig CR, Rundle JS: Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology. 1989; 33: 175-8.
18. Koutsilieris M, Faure N, Tolis G, Laroche B, Robert G, Ackman CF: Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome. Urology. 1986; 27: 221-8.
19. Sharifi R, Knoll LD, Smith J, Kramolowsky E: Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology. 1998; 51:271-6.
20. Fernandez del Moral P, Dijkman GA, Debruyne FM, Witjes WP, Kolvenbag GJ: Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Urology. 1996; 48: 894-900.
21. Nyman CR, Andersen JT, Lodding P, Sandin T, Varenhorst E: The patient's choice of androgendeprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy. BJU Int. 2005; 96: 1014-8.
22. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998; 339: 1036-42.
23. The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer.. N Engl J Med. 1984; 311: 1281-6.
24. Metz R, Namer M, Adenis L, Audhuy B, Bugat R, Colombel P, et al.: Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial. Am J Clin Oncol. 1988; 11 (Suppl 2): S 112-4.
25. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al.: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol. 2000; 164: 1579-82.
26. Langenstroer P, Kramer B, Cutting B, Amling C, Poultan T, Lance R, et al.: Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol. 2005; 174: 642-5.